BioSenic S.A. (BIOSB.XC)
- GlobeNewswire
BioSenic S.A. : Information on the total number of voting rights and shares
PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, June 28, 2024, 7.00 am CET – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published in accordance with Article 15 of the Belgian law of 2 May 2007 on the publication of major sha
- GlobeNewswire
BioSenic signs a new subscription agreement for a maximum of EUR 2.1M in convertible bonds
PRESS RELEASE – PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, June 21, 2024 6.00pm CEST – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces that it has signed a new subscription agreement for a maximum EUR 2.1 million convertible bonds ("CBs") facility, arranged by ABO Securities through its affiliated entity Global Tech Opportunities 15 ("GTO 15"). GTO 15 has committed to s
- Globe Newswire
The Enterprise Court of Nivelles approves the BioSenic restructuring plan
PRESS RELEASE – PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, June 14, 2024 7.00am CEST – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases, as well as cell repair, announces that it has received the homologation judgment for the restructuring plan filed with the Enterprise Court of Nivelles. This homologation judgment makes the plan binding on all deferred creditors, and the measures provided for therein w
